Gilead Sciences, Inc. - Q2 2007 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2007. Gilead Sciences, Inc. is a biopharmaceutical company focused on HIV, Hepatitis B, and other life-threatening diseases. Key products include Truvada, Atripla, Viread, Emtriva, Hepsera, and AmBisome. In June 2007, the company launched Letairis for pulmonary arterial hypertension following FDA approval. The company completed a two-for-one stock split effective June 22, 2007, and all share data is retroactively adjusted.
Key Financial Metrics
| Metric (in millions) | Q2 2007 | Q2 2006 | YTD 2007 | YTD 2006 |
|---|---|---|---|---|
| Total Revenues | $1,048.1 | $685.3 | $2,076.5 | $1,378.2 |
| Net Income | $407.9 | $265.2 | $815.3 | $527.9 |
| Diluted EPS | $0.42 | $0.28 | $0.85 | $0.55 |
| Product Gross Margin | 80% | 87% | 80% | 85% |
| Operating Cash Flow (YTD) | $1,002.2 | $487.8 | $1,002.2 | $487.8 |
| Cash & Marketable Securities | $1,987.1 | $1,389.6 | $1,987.1 | $1,389.6 |
| Convertible Senior Notes | $1,300.0 | $1,300.0 | $1,300.0 | $1,300.0 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 53% in Q2 and 51% YTD compared to 2006. Product sales grew 53% (Q2) and 52% (YTD), driven primarily by a 60% increase in HIV product sales.
- Product Mix: Atripla sales reached $212.4 million in Q2 (no prior year comparison as it launched in July 2006). Truvada sales grew 29% to $385.4 million. Viread sales declined 7% to $154.9 million due to lower volume in the U.S. and Europe.
- Royalty Revenue: Royalty revenue surged 59% to $135.7 million in Q2, largely due to a 68% increase in Tamiflu royalties from Roche ($123.1 million recognized in Q2).
- Expenses: R&D expenses increased 50% to $135.9 million (Q2) due to expanded clinical trials in respiratory and cardiopulmonary programs. SG&A expenses rose 23% to $186.2 million, driven by headcount increases and the launch of Letairis.
- Stock Repurchases: The company completed its $1.0 billion stock repurchase program, spending $454.9 million in Q2 2007 to retire 11.2 million shares.
Guidance, Outlook, and Risks
- Outlook: Management expects total product sales for full-year 2007 to increase from 2006 levels. However, product gross margins are expected to be lower than 2006 due to the higher mix of Atripla sales (which includes Sustiva at zero gross profit).
- Pipeline: The company intends to file an NDA for Viread for chronic hepatitis B in Q4 2007 and an NDA for aztreonam lysine for cystic fibrosis in the second half of 2007.
- Risks:
- Product Concentration: HIV products accounted for 73% of total revenues in Q2 2007. Atripla and Truvada alone represented 79% of HIV sales.
- Tamiflu Dependency: While Tamiflu royalties were less than 12% of total revenue, they represented 22% of pre-tax income in Q2 2007. Sales are volatile and tied to pandemic planning.
- Regulatory & Safety: Letairis carries risks of liver injury and birth defects, requiring a restricted distribution program. The company faces potential patent challenges and generic competition.
- Legal: The company is named in a Medicaid pricing lawsuit and is cooperating with a U.S. Attorney's Office investigation regarding marketing practices for Truvada, Viread, and Emtriva.
Investor Verification Checklist
- Verify the sustainability of HIV product growth rates given the maturity of the market and potential generic competition.
- Assess the volatility of pre-tax income due to the high proportion of Tamiflu royalties relative to total revenue.
- Monitor the impact of the Atripla product mix on overall gross margins, specifically the zero-margin component related to Sustiva.
- Review the status of the U.S. Attorney's Office investigation and the pending Medicaid pricing litigation.
- Confirm the timeline and success probability of the pending NDAs for Viread (Hepatitis B) and aztreonam lysine (Cystic Fibrosis).